| Naïve comparison: ORR of 70.4% for remestemcel-L-rknd versus 57.1% for ruxolitinib |
| ITC (unadjusted) |
1.21
|
0.90-1.63
|
0.21
|
| STC (adjusted) |
1.13
|
0.83-1.63
|
0.45
|
| ITC (unadjusted, grade III-IV aGVHD) |
1.72
|
1.12-2.63
|
0.01
|
| STC (adjusted, grade III-IV aGVHD) |
1.58
|
1.02-2.33
|
0.04
|